Myer Vickesh 4
4 · Editas Medicine, Inc. · Filed Jan 18, 2019
Insider Transaction Report
Form 4
Myer Vickesh
Chief Technology Officer
Transactions
- Exercise/Conversion
Common Stock
2019-01-18$11.21/sh+4,000$44,840→ 4,000 total - Exercise/Conversion
Stock Option (right to buy)
2019-01-17−3,000→ 79,307 totalExercise: $0.65Exp: 2025-04-29→ Common Stock (3,000 underlying) - Sale
Common Stock
2019-01-17$26.18/sh−3,000$78,540→ 0 total - Exercise/Conversion
Common Stock
2019-01-17$0.65/sh+3,000$1,950→ 3,000 total - Sale
Common Stock
2019-01-18$26.50/sh−4,000$106,000→ 0 total - Exercise/Conversion
Stock Option (right to buy)
2019-01-18−4,000→ 52,897 totalExercise: $11.21Exp: 2025-10-29→ Common Stock (4,000 underlying)
Footnotes (4)
- [F1]The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2017.
- [F2]This transaction was executed in multiple trades at prices ranging from $26.03 to $26.41. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and the prices at which the transaction was effected.
- [F3]This option was granted on April 30, 2015 and is scheduled to vest over four years, with 25% of the shares having vested on April 21, 2016, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through April 21, 2019.
- [F4]This option was granted on October 30, 2015 and is scheduled to vest over four years, with 25% of the shares having vested on October 27, 2016 and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through October 27, 2019.